bioAffinity Technologies

bioAffinity Technologies Addressing the need for noninvasive diagnosis of early-stage cancer and targeted cancer treatment. www.cypathlung.com

Our flagship product, CyPath® Lung, is a noninvasive early lung cancer diagnostic.

bioAffinity Technologies (Nasdaq: BIAF) reported second quarter 2026 financial results and continued strong commercial m...
08/07/2026

bioAffinity Technologies (Nasdaq: BIAF) reported second quarter 2026 financial results and continued strong commercial momentum for CyPath® Lung.

As physician adoption continued to grow, CyPath® Lung test volume increased 216% year over year, supporting continued commercial expansion of the company's noninvasive lung cancer diagnostic. During the quarter, bioAffinity also advanced enrollment in its longitudinal clinical trial and continued expanding its pipeline with precision diagnostics for asthma and COPD.

Read more: https://bit.ly/4hVySkc

08/07/2026

Physicians often rely on multiple sources of clinical information to evaluate pulmonary nodules for cancer.

CyPath Lung investigates a patient’s sputum using flow cytometry+AI technology to provide a real-time assessment of the lung microenvironment. By identifying cancer and cancer-related cells, CyPath Lung complements imaging and other clinical findings for better patient outcomes.

Learn more: https://www.cypathlung.com/

08/05/2026

The period between discovering a pulmonary nodule and determining next steps can be stressful for patients.

CyPath Lung provides additional diagnostic information to help physicians assess malignancy risk. That additional insight also helps patients better understand their options and participate in conversations about their care.

This physician knows that a negative CyPath Lung test result eases a patient’s anxiety and provides reassurance about next steps.

Learn more: https://www.cypathlung.com/

Managing indeterminate pulmonary nodules often requires input from multiple specialties.In the newest CyPath® Lung Conne...
08/04/2026

Managing indeterminate pulmonary nodules often requires input from multiple specialties.

In the newest CyPath® Lung Connect Forums, an interventional pulmonologist, thoracic surgeon and medical oncologist discuss the growing number of pulmonary nodules being identified in high-risk patients, the limitations of current risk-stratification approaches and where CyPath® Lung fits into the diagnostic pathway. The discussion explores how objective information can help inform decisions about follow-up, surveillance and biopsy.

Listen now on Spotify, Apple Podcasts, Amazon Music and other major podcast platforms.

Spotify: https://open.spotify.com/episode/1SVIYMzVx2WO9pL0pNzM2D

Apple Podcasts: https://podcasts.apple.com/us/podcast/navigating-lung-nodules-in-high-risk-patients-the/id1896873418?i=1000779875895

08/01/2026

Every lung cancer diagnosis represents a person, a family and a community.

As we mark today, we recognize those living with lung cancer, remember those we've lost and continue to support the healthcare professionals, researchers and advocates working to improve outcomes for patients everywhere.

Together, we can help raise awareness about the importance of screening, early detection and access to care. https://www.cypathlung.com/

07/31/2026

No two patient journeys are exactly alike.

CyPath Lung provides additional diagnostic information that supports physicians evaluating pulmonary nodules as part of the overall clinical assessment. The flow cytometry+AI test is designed to complement existing diagnostic tools and contribute to informed patient management decisions.

Learn more: https://www.cypathlung.com/

A closer look at the lungs provides information blood tests cannot capture.bioAffinity Technologies' new white paper hig...
07/30/2026

A closer look at the lungs provides information blood tests cannot capture.

bioAffinity Technologies' new white paper highlights the value of using CyPath Lung to evaluate sputum collected directly from the lungs to risk stratify patients at risk for lung cancer and detect the disease as early as Stage 1A when it is most treatable.

Learn more about how CyPath® Lung complements imaging and other clinical findings during pulmonary nodule evaluation: https://bit.ly/4pE16BW

07/29/2026

Risk stratification is one way clinicians determine the most appropriate path forward for patients with indeterminate pulmonary nodules.

CyPath Lung provides additional diagnostic information that helps clinicians assess malignancy risk and provides assurance to anxious patients that they are undergoing an invasive biopsy for the right reasons.

Learn more: https://www.cypathlung.com/

Every pulmonary nodule tells only part of the story. When alone doesn't tell the whole story, physicians need more inf...
07/27/2026

Every pulmonary nodule tells only part of the story. When alone doesn't tell the whole story, physicians need more information.

bioAffinity Technologies (Nasdaq: BIAF) has published a new white paper examining how CyPath® Lung fits into pulmonary nodule evaluation across pulmonology, primary care and oncology. The challenge is determining which patients need invasive procedures and which can be safely monitored.

Drawing on three years of commercial experience, the publication presents a practical clinical framework for using CyPath® Lung's flow cytometry+AI platform to detect lung cancer and surveil survivors.

Read the white paper and news release: https://bit.ly/4pE16BW

07/24/2026

At 85 years old and a history of lung disease, avoiding an unnecessary invasive medical procedure can be a good thing.

CyPath Lung provided this physician with additional diagnostic insight about his patient’s pulmonary nodule that helped avoid a risky biopsy. Follow-up monitoring showed resolution of the nodule without further intervention.

CyPath Lung’s flow cytometry+AI technology supports individualized patient management and more informed decision-making.

Learn more: https://www.cypathlung.com/

Address

3300 Nacogdoches Road Ste 216
San Antonio, TX
78217

Telephone

+12106985334

Website

Alerts

Be the first to know and let us send you an email when bioAffinity Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category